Robigo and Leaps by Bayer have closed a Series A financing round to advance engineered microbial products that the companies say match the performance of commercially available chemistries against sudden death syndrome (SDS) in soybeans at roughly half the per-acre cost.

The funding, announced in February, positions the startup to move its lead biological candidate toward a commercial launch targeted for 2028, according to the announcement carried by CropLife. Financial terms of the Series A were not disclosed.

What the product targets

Robigo's platform engineers naturally occurring soil microbes to deliver targeted disease control. The lead program focuses on sudden death syndrome, a soilborne fungal disease caused by Fusarium virguliforme that ranks among the most economically damaging soybean diseases in the United States. Infected plants display interveinal yellowing and premature defoliation during reproductive stages, with severe outbreaks pulling yields well below trend in affected fields.

How the cost story is framed

The company states its engineered microbes perform on par with conventional SDS chemistries — primarily fungicide seed treatments — at approximately 50% of the input cost. That comparison lands at a moment when soybean growers are tracking every input line for margin recovery, given soybean futures near multi-year averages and elevated costs for seed, fertilizer and land.

Why the Bayer tie-in matters

Leaps by Bayer is Bayer's venture arm for investments in breakthrough technologies spanning agriculture and health. The partnership gives Robigo a path to Bayer's distribution channels, regulatory capabilities and seed-treatment formulation expertise — capabilities that matter for any biological product that must remain viable on the seed from treatment through planting.

What the 2028 launch implies

A 2028 commercial launch would put Robigo's product among a wave of biological fungicide candidates advancing through U.S. regulatory pipelines. Growers evaluating the segment over the next three growing seasons will weigh whether university and third-party trial data replicate the company's efficacy claims, how the microbe performs in continuous-corn or tight soybean rotations that also host SDS, and whether seed-treatment compatibility extends to the branded soybean treatments that already dominate the marketplace.

What the announcement doesn't say

The release provides no detail on the size of the Series A round, additional participating investors, field-trial geographies, replicated third-party yield comparisons or the specific U.S. soybean-producing states the company will target first. Those data points will determine whether the half-cost claim holds up at scale.

For input manufacturers and biologicals competitors, the round signals Bayer's intent to build a microbial pipeline that complements its traditional chemistry portfolio rather than simply replacing it.